Panacea Life Sciences readies national launch after beta test

Panacea Life Sciences Holdings said BeniVita BioHealth has finished beta testing its telemedicine and peptide platform and is preparing a national launch in Q4 2026. The company is also lining up distribution, marketing and leadership changes as it expands into U.S.-sourced peptide and telemedicine operations.

Why it matters: - Panacea Life Sciences Holdings is moving BeniVita BioHealth from testing into a planned national rollout in Q4 2026. - The expansion could connect telemedicine, peptide distribution and digital marketing under one platform. - The company is also positioning for domestic sourcing of active pharmaceutical ingredients, which it says supports scale and compliance.

What happened: - BeniVita BioHealth completed the beta phase of its proprietary technology and infrastructure for telemedicine and peptide platforms. - The beta ran through the first two quarters of fiscal 2026. - BeniVita BioHealth introduced the technology into a dozen U.S. markets during the testing period. - Panacea Life Sciences Holdings said BeniVita BioHealth is now positioned for a full national launch in Q4 2026. - The distribution, vendor, marketing and technology agreements described in the release were entered into by BeniVita, Inc.

The details: - Panacea Life Sciences Holdings expects BeniVita BioHealth to enter back-to-back operating agreements with BeniVita, Inc. and share revenue from those agreements. - The company expects those agreements to be completed in Q4 2026, subject to final documentation and any required counterparty consents. - There is no assurance the agreements will close on that timeline or at all. - BeniVita, Inc. has a distribution agreement with the largest peptide manufacturer in the United States. - BeniVita, Inc. also has a contractual relationship with a national telemedicine physician network to support the peptide business. - Once the back-to-back agreements are completed, BeniVita BioHealth is expected to market and distribute active pharmaceutical ingredients sourced entirely within the United States. - The domestic sourcing strategy is intended to support a scalable supply and distribution channel in the peptide and telemedicine markets. - The strategy is also meant to support compliance with applicable U.S. manufacturing and sourcing guidelines. - BeniVita engaged AG & Lora Communications, a Latino-focused public relations firm founded by Willie Lora and Andrea Gomez. - BeniVita also partnered with DigiClicks, led by former senior YouTube executives Lina Mateus and Diana Valdez, to build and execute its digital marketing strategy. - Those firms will support customer acquisition focused on the U.S. Latino market, especially Spanish-speaking consumers. - BeniVita partnered with Luis Rodriguez of iQmindset on an AI-powered business technology platform for ambassadors. - The platform combines CRM, marketing automation, social media, websites, sales funnels, scheduling, reputation management and AI-driven business intelligence. - Panacea Life Sciences Holdings expects the iQmindset system to help ambassadors work more efficiently and scale the telemedicine and peptide businesses. - The company expects current CEO Leslie Buttorff to retire during fiscal 2026. - Jon Guzman, CEO of BeniVita, Inc., is expected to become CEO of Panacea Life Sciences Holdings and BeniVita BioHealth. - Panacea Life Sciences Holdings expects to add two more board members in the coming weeks. - Larry Wert, a board member, has more than four decades of experience in television, digital media and radio, including senior roles at NBC and Tribune Media. - BeniVita BioHealth’s executive team includes Darren Holden as vice president of sales, Santiago Esparza as national master distributor, Kevin Grimes as president and general counsel of BeniVita, David Bertao as chief operating officer, Eric Ulwelling as chief financial officer, and Jessica Marie Gutierrez Guzman as chief marketing and technology officer. - Panacea Life Sciences Holdings expects to announce additional leadership team members as expansion continues. - The company plans to release an updated pro forma for fiscal 2027 and an expanded business strategy at the end of October 2026. - That update is expected to include more detail on digital strategy, distribution relationships, the telemedicine platform and the peptide business. - Panacea Life Sciences Holdings plans to form BeniVita BioTech as a new subsidiary focused on additional healthcare technologies. - BeniVita is preparing a non-binding memorandum of understanding for technology that would deliver telemedicine services to blind and deaf users through a mobile device. - If that license is secured, Panacea Life Sciences Holdings and BeniVita expect to make rights available to BeniVita BioTech through a back-to-back or similar agreement. - The technology developer already has licensing agreements with the Indianapolis 500 and Major League Baseball for broadcasting content to blind users through the device. - BeniVita also intends to pursue a Medicare reimbursement code for the technology. - BeniVita is in final negotiations for a $6 million private equity capital raise for its own operations. - Panacea Life Sciences Holdings is not a party to that financing.

Between the lines: - The release shows a company building a vertically integrated model around distribution, marketing, technology and leadership control before a wider launch. - The repeated focus on U.S. sourcing, Latino-targeted outreach and AI-enabled sales tools suggests BeniVita BioHealth wants a national consumer business with a tightly managed operating stack. - Much of the plan still depends on agreements that have not been finalized, so the launch story is more about preparation than completed scale.

What's next: - Panacea Life Sciences Holdings expects back-to-back operating agreements to be completed in Q4 2026. - The company plans to announce the CEO transition during fiscal 2026. - Panacea Life Sciences Holdings expects more board appointments in the coming weeks. - The updated fiscal 2027 pro forma and expanded strategy are due at the end of October 2026. - BeniVita may also pursue the accessibility technology license, Medicare coding and a new financing round for BeniVita's own operations.

The bottom line: - Panacea Life Sciences Holdings is trying to turn a beta-tested telemedicine and peptide platform into a national business, but the next phase still hinges on pending agreements and approvals.